Cullinan Therapeutics, INC

Cullinan Therapeutics stockholders re-elected two directors, ratified KPMG LLP as auditors, and approved executive compensation.

Cullinan Therapeutics announced updated clinical data for CLN-978 in rheumatoid arthritis and lupus, showing potential for remission, and initial data for velinotamig in lupus nephritis, demonstrating complete renal responses.

Cullinan Therapeutics announced initial clinical data from its Phase 1 OUTRACE trials for CLN-978, showing clinical benefit and B cell depletion in patients with rheumatoid arthritis and systemic lupus erythematosus.

Cullinan Therapeutics announced promising initial Phase 1 clinical data for its CD19xCD3 T cell engager, CLN-978, in patients with refractory rheumatoid arthritis and systemic lupus erythematosus.

Cullinan Therapeutics announced Q1 2026 financial results, highlighting FDA acceptance of the zipalertinib NDA and upcoming clinical data presentations for CLN-978.

Cullinan Therapeutics announced preliminary cash of $439 million, extending its runway into 2029, alongside significant clinical progress and upcoming data readouts for its immunology and oncology programs.

Cullinan Therapeutics reports Q1 2026 results, with a net loss of $49.7 million and cash reserves projected to fund operations for at least 12 months.

Cullinan Therapeutics reported a wider net loss in Q3 2025, driven by increased R&D expenses including a $20 million license fee for velinotamig, while advancing key oncology and immunology programs and discontinuing others.

Cullinan Therapeutics reported increased Q2 losses driven by higher R&D expenses, including a new $20 million license, while advancing its clinical pipeline with positive zipalertinib data and new autoimmune programs.

Cullinan Therapeutics announces its financial results for the first quarter of 2025, highlighting progress in its clinical programs and providing an update on its financial position.

Cullinan Therapeutics reported its financial results for the third quarter of 2024, highlighting progress in its clinical programs and a strong cash position.

Cullinan Therapeutics reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs and a recent private placement that raised $262.7 million.

Cullinan Therapeutics' 2024 10-K filing highlights clinical progress across its immunology and oncology pipeline, including key milestones for CLN-978, CLN-619, and zipalertinib.

Cullinan Oncology's 10-K filing highlights a diverse pipeline of oncology therapies and a strong financial position to support ongoing development.

Cullinan Therapeutics reports insider transactions involving common stock and stock options by Chief Scientific Officer Jennifer Michaelson.

Jacquelyn Sumer, Chief Legal Officer at Cullinan Therapeutics, Inc., reported the acquisition of 2,470 shares of common stock through the company's Employee Stock Purchase Plan.

Cullinan Therapeutics' Chief Financial Officer, Mary Kay Fenton, has acquired 1,541 shares of common stock through the company's Employee Stock Purchase Plan.

Cullinan Therapeutics director Anthony Rosenberg acquired stock options for 25,319 shares of common stock.

David D. Meek, a director at Cullinan Therapeutics, Inc., acquired stock options for 25,319 shares of common stock on June 16, 2026.

Cullinan Therapeutics, Inc. reports that Director Mary Thistle acquired stock options for 25,319 shares of common stock.

Cullinan Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 16, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Cullinan Therapeutics has scheduled its 2025 Annual Meeting for June 12, 2025, and is seeking stockholder votes on director elections, auditor ratification, and executive compensation.

Cullinan Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 12, 2025, featuring director elections, auditor ratification, and executive compensation advisory votes.

Cullinan Therapeutics has scheduled its annual stockholder meeting for June 26, 2024, featuring proposals for director elections and the ratification of KPMG LLP as the independent accounting firm.

Cullinan Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 26, 2024, to vote on the election of directors and the ratification of the company's independent auditor.

Biotechnology Value Fund and affiliates report a 9.99% beneficial ownership stake in Cullinan Therapeutics, Inc. following recent share conversions.

The Vanguard Group has reported a 0% beneficial ownership in Cullinan Therapeutics Inc. following an internal realignment.

Kynam Capital Management, LP, along with its general partner and managing member, has reported a beneficial ownership of 5.27% in Cullinan Therapeutics, Inc. as of December 31, 2025.

The Vanguard Group reported a 5.58% beneficial ownership stake in Cullinan Therapeutics Inc. common stock as of December 31, 2025.

Citadel and its affiliates, including Kenneth Griffin, have disclosed a combined beneficial ownership of 3.4% in Cullinan Therapeutics, Inc.

Lynx1 Capital Management LP and Weston Nichols reported a 9.8% beneficial ownership stake in Cullinan Therapeutics, Inc. as of September 30, 2025.